Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.69 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.64 |
| ▸ | ALPI | P09923 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | XIAP | P98170 | 1/20 | 0.54 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.54 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 2/20 | 0.47 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16657025 | 1.00 | LTA4H (0.69) | LTA4HSLC15A1ALPIPKMPTGS1 | |
| SCHEMBL13515476 | 0.94 | LTA4H (0.73) | LTA4HSLC15A1ALPIPKMPTGS1 | |
| SCHEMBL15244990 | 0.87 | SLC15A1 (0.72) | LTA4HSLC15A1ALPIPKMPTGS1 | |
| SCHEMBL12433005 | 0.87 | SLC15A1 (0.72) | LTA4HSLC15A1ALPIPKMPTGS1 | |
| SCHEMBL20630639 | 0.87 | SLC15A1 (0.72) | LTA4HSLC15A1ALPIPKMPTGS1 | |
| Tetradecane SCHEMBL21002171 | 0.85 | SLC7A5 (0.76) | LTA4HSLC15A1ALPIPKMPTGS1 | |
| Dodecanoate SCHEMBL599338 | 0.85 | ALPI (0.65) | LTA4HSLC15A1ALPIPKMPTGS1 | |
| Dl-Phenylalanine SCHEMBL598090 | 0.85 | ALPI (0.65) | LTA4HSLC15A1ALPIPKMPTGS1 | |
| Dodecanoate SCHEMBL599337 | 0.85 | ALPI (0.65) | LTA4HSLC15A1ALPIPKMPTGS1 | |
| Decanoic Acid SCHEMBL17667545 | 0.85 | ALPI (0.65) | LTA4HSLC15A1ALPIPKMPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4682144-A1 | SOLID FORM OF PYRROLIDONE DERIVATIVE AS GLUCOKINASE ACTIVATOR | Hua Medicine (Shanghai) Ltd. (CN) | 2026-01-21 | — | — | EP | disclosed |
| US-20250171458-A1 | METHOD FOR SYNTHESIZING 1H-FURO[3,2-B]IMIDAZO[4,5-D]PYRIDINE COMPOUND | HANGZHOU HIGHLIGHTLL PHARMACEUTICAL CO., LTD (CN) | 2025-05-29 | — | — | US | disclosed |
| EP-4509509-A1 | METHOD FOR SYNTHESIZING 1H-FURO[3,2-B]IMIDAZO[4,5-D]PYRIDINE COMPOUND | Hangzhou Highlightll Pharmaceutical Co., Ltd (CN) | 2025-02-19 | — | — | EP | disclosed |
| EP-3781661-B1 | TETRAACETYLDIAMINE AND TRIACETYLDIAMINE DERIVATIVES USEFUL AS BLEACH ACTIVATORS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2024-03-13 | — | — | EP | disclosed |
| US-11525106-B2 | Tetraacetyldiamine and triacetyldiamine derivatives useful as bleach activators | DOW GLOBAL TECHNOLOGIES LLC (US) | 2022-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171458-A1 | METHOD FOR SYNTHESIZING 1H-FURO[3,2-B]IMIDAZO[4,5-D]PYRIDINE COMPOUND | BMP4, AZI2, CYP4B1 | LTA4H 4021/4885SLC15A1 4551/4885ALPI 3295/4885 |
| US-11525106-B2 | Tetraacetyldiamine and triacetyldiamine derivatives useful as bleach activators | AADAC, DLAT, NAT10 | LTA4H 356/4885SLC15A1 4726/4885ALPI 3324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.